Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Cameron J Herting

Showing results (11-20 of 17) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 17 results.
Oncoimmunology|March 13, 2025
XL888 and pembrolizumab modulate the immune landscape of colorectal tumors in a phase Ib/II clinical trialMaggie J Phillips, Olatunji B Alese, Natalie K Horvat, et al.
Cancer Letters|December 25, 2025
A phase Ib/II trial of XL888 (HSP90 inhibitor) and pembrolizumab in metastatic pancreatic cancer with translational immune profilingNatalie K Horvat, Maria Diab, Maggie J Phillips, et al.
The Journal of Clinical Investigation|September 21, 2023
A paracrine circuit of IL-1β/IL-1R1 between myeloid and tumor cells drives genotype-dependent glioblastoma progressionZhihong Chen, Bruno Giotti, Milota Kaluzova, et al.
JCI Insight|March 7, 2023
Dual IL-6 and CTLA-4 blockade regresses pancreatic tumors in a T cell- and CXCR3-dependent mannerMichael Brandon Ware, Maggie Phillips, Christopher McQuinn, et al.
Oncoimmunology|October 25, 2019
Human Mesenchymal glioblastomas are characterized by an increased immune cell presence compared to Proneural and Classical tumorsIoannis Kaffes, Frank Szulzewsky, Zhihong Chen, et al.
Cancer Research|December 19, 2025
High-Dimensional Protein Analysis Uncovers Distinct Immunological and Stromal Features in Primary and Metastatic Pancreatic Ductal AdenocarcinomaEmily Greene, Natalie K Horvat, Deon Bryant Doxie, et al.
Science Translational Medicine|February 15, 2019
IDH1-R132H acts as a tumor suppressor in glioma via epigenetic up-regulation of the DNA damage responseFelipe J Núñez, Flor M Mendez, Padma Kadiyala, et al.
Pageof 2

Showing results (11-20 of 17) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 17 results.
Oncoimmunology|March 13, 2025
XL888 and pembrolizumab modulate the immune landscape of colorectal tumors in a phase Ib/II clinical trialMaggie J Phillips, Olatunji B Alese, Natalie K Horvat, et al.
Cancer Letters|December 25, 2025
A phase Ib/II trial of XL888 (HSP90 inhibitor) and pembrolizumab in metastatic pancreatic cancer with translational immune profilingNatalie K Horvat, Maria Diab, Maggie J Phillips, et al.
The Journal of Clinical Investigation|September 21, 2023
A paracrine circuit of IL-1β/IL-1R1 between myeloid and tumor cells drives genotype-dependent glioblastoma progressionZhihong Chen, Bruno Giotti, Milota Kaluzova, et al.
JCI Insight|March 7, 2023
Dual IL-6 and CTLA-4 blockade regresses pancreatic tumors in a T cell- and CXCR3-dependent mannerMichael Brandon Ware, Maggie Phillips, Christopher McQuinn, et al.
Oncoimmunology|October 25, 2019
Human Mesenchymal glioblastomas are characterized by an increased immune cell presence compared to Proneural and Classical tumorsIoannis Kaffes, Frank Szulzewsky, Zhihong Chen, et al.
Cancer Research|December 19, 2025
High-Dimensional Protein Analysis Uncovers Distinct Immunological and Stromal Features in Primary and Metastatic Pancreatic Ductal AdenocarcinomaEmily Greene, Natalie K Horvat, Deon Bryant Doxie, et al.
Science Translational Medicine|February 15, 2019
IDH1-R132H acts as a tumor suppressor in glioma via epigenetic up-regulation of the DNA damage responseFelipe J Núñez, Flor M Mendez, Padma Kadiyala, et al.
Pageof 2